• AP20187: Chemical Inducer of Dimerization for Precision Cont

  2026-06-07

  AP20187 empowers researchers with on-demand control over protein interactions in conditional gene expression systems, unlocking precision in metabolic, hematopoietic, and cancer biology studies. Its high solubility, rapid cell permeability, and proven in vivo efficacy make it a gold-standard chemical inducer of dimerization for advanced gene therapy and signaling pathway activation.

• AG-126 (Tyrphostin AG-126): Precision ERK Inhibition in Neur

  2026-06-06

  AG-126 (Tyrphostin AG-126) stands out as a highly selective ERK1/2 inhibitor, enabling researchers to dissect MAPK/ERK pathway dynamics in models of neuroinflammation and autism-related behaviors. Discover workflow optimizations, troubleshooting strategies, and practical cross-links to published breakthroughs that leverage AG-126 for reproducible, high-impact results.

• Anlotinib Hydrochloride (SKU C8688): Precision in Angiogenes

  2026-06-05

  This scenario-driven guide equips biomedical researchers and lab technicians with evidence-based protocols for using Anlotinib hydrochloride (SKU C8688) in cell viability, proliferation, and angiogenesis assays. Drawing on peer-reviewed data and real lab challenges, it demonstrates how Anlotinib hydrochloride delivers reproducible, sensitive, and safe results—making it an indispensable tool for modern cancer research workflows.

• Advanced In Vitro Approaches for Evaluating PARP Inhibitors

  2026-06-05

  Schwartz's dissertation introduces a nuanced in vitro framework for distinguishing drug-induced proliferation arrest from cell death in cancer models, emphasizing the distinct measurement of relative and fractional viability. These methodological refinements enable more precise evaluation of novel PARP inhibitors, such as AZD2461, and have significant implications for breast cancer research and drug resistance studies.

• RNASEH1-AS1 as Prognostic lncRNA and Target in Hepatocellula

  2026-06-04

  This study identifies the long non-coding RNA RNASEH1-AS1 as a robust prognostic biomarker and oncogenic target in hepatocellular carcinoma (HCC). Through integrative bioinformatics and experimental validation, the research delineates RNASEH1-AS1's diagnostic potential and mechanistic involvement in tumor progression, highlighting its value for future RNA-focused cancer studies.

• ABT-263 (Navitoclax): Redox Imaging and Mitochondrial Dynami

  2026-06-04

  Explore how ABT-263 (Navitoclax) enables advanced mitochondrial and metabolic profiling in cancer biology using optical redox ratio imaging. This article reveals assay design insights and mechanistic nuances not covered in standard apoptosis workflows.

• KU-60019: Precision ATM Inhibition for Synergistic Cancer St

  2026-06-03

  Explore how KU-60019, a potent ATM kinase inhibitor, enables next-generation assay design and combination therapies, extending far beyond radiosensitization. This article delivers actionable insights for advanced cancer research.

• Targeting BCL-XL and MCL-1 in Glioblastoma: Insights from BH

  2026-06-03

  The reference study identifies elevated BCL-XL and MCL-1 expression as a key vulnerability in glioblastoma, rendering these tumors highly sensitive to BH3-mimetic–mediated apoptosis. Sequential inhibition of these anti-apoptotic proteins produces robust tumor control in preclinical models, supporting a rational strategy to overcome therapy resistance in GBM and potentially other malignancies.

• AS1842856 Foxo1 Inhibitor: Precision Tool for Gluconeogenesi

  2026-06-02

  AS1842856 Foxo1 Inhibitor enables targeted modulation of gluconeogenesis and autophagy in metabolic disease models, offering high specificity and reproducibility. Its application streamlines workflows investigating Foxo1-mediated gene regulation and supports advanced studies in MSC activation and metabolic dysfunction.

• Improving In Vitro Drug Response Assessment in Cancer Resear

  2026-06-02

  Schwartz's dissertation advances cancer pharmacology by dissecting the distinct roles of growth inhibition and cell death in response to anti-cancer agents. By establishing clear methodologies for quantifying these effects, the study offers researchers refined metrics for evaluating drug efficacy in vitro—paving the way for more precise, predictive preclinical testing.

• MCL-1’s Canonical Anti-Apoptotic Role in Breast Cancer Survi

  2026-06-01

  The reference study by Campbell et al. rigorously demonstrates that breast cancer cell survival and tumor maintenance are critically dependent on the canonical anti-apoptotic function of MCL-1. By combining genetic and pharmacological approaches, the work establishes that targeting MCL-1’s role in apoptosis—rather than its non-apoptotic functions—is key to effective intervention, with direct implications for the use of selective MCL-1 inhibitors in cancer research.

• Stattic STAT3 Inhibitor: Optimizing Cancer Cell Assays

  2026-06-01

  Stattic delivers precise, reproducible STAT3 inhibition for dissecting oncogenic signaling in cancer biology. This article translates cutting-edge research—including the gut microbiome’s role in STAT3-driven cancer progression—into actionable workflows, advanced use-cases, and troubleshooting strategies for head and neck squamous cell carcinoma and beyond.

• CX-5461: RNA Polymerase I Inhibitor Workflows in Cancer Rese

  2026-05-31

  CX-5461 is redefining cancer research as a selective, potent RNA polymerase I inhibitor that enables ribosome biogenesis targeting, autophagy induction, and cellular senescence in solid tumor models. This guide details optimized workflows, troubleshooting strategies, and the latest insights from advanced studies—including combinatorial regimens for overcoming chemoresistance.

• Icatibant in Viral Infections: Insights for Antiviral Resear

  2026-05-30

  The reference study examines the clinical use of icatibant, a bradykinin B2 receptor antagonist, in severe viral infections such as hantavirus (PUUV) and COVID-19. It highlights both the potential benefits and the underlying pathophysiological rationale for targeting the kinin-kallikrein system in these settings, while emphasizing the need for more systematic research to clarify efficacy and timing of intervention.

• Biotin-16-UTP: Protocols and QC for RNA Labeling Workflows

  2026-05-29

  Biotin-16-UTP enables precise incorporation of biotin-labeled uridine into RNA during in vitro transcription, facilitating efficient RNA detection and purification. It is intended strictly for research applications and should not be used in diagnostic or clinical workflows. Proper storage and handling are essential to maintain reagent quality and experimental reliability.

8077 records 14/539 page Previous Next First page 上5页 1112131415 下5页 Last page